Division of Gastroenterology and Hepatology, UNC Liver Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7584, USA.
Liver Int. 2012 Feb;32 Suppl 1(0 1):151-6. doi: 10.1111/j.1478-3231.2011.02706.x.
Despite the availability of highly effective therapy for hepatitis C virus (HCV) infection, few patients receive treatment. Barriers arising at multiple levels, from diagnosis to specialist referral, may impede the delivery of hepatitis C care. At the patient level, lack of awareness, fear of side effects, poor adherence and comorbid conditions may prevent treatment. For providers, limited knowledge, lack of availability and communication difficulties may be problematic. At the government and payer level, a lack of promotion, surveillance and funding may interfere. Each of these barriers needs to be addressed if wider implementation of antiviral therapy is to be achieved.
尽管已有针对丙型肝炎病毒 (HCV) 感染的高效疗法，但仍有少数患者接受治疗。从诊断到专科转诊，多个层面上存在的障碍可能会阻碍丙型肝炎治疗的开展。在患者层面，缺乏意识、对副作用的恐惧、治疗依从性差和合并症等因素可能会导致治疗受阻。对于医疗服务提供者来说，知识有限、资源缺乏和沟通困难等问题也会带来挑战。在政府和支付方层面，宣传、监测和资金不足等问题也可能会造成阻碍。如果要更广泛地实施抗病毒治疗，就需要解决这些障碍中的每一个。
